Form 8-K - Current report:
SEC Accession No. 0001213900-25-054961
Filing Date
2025-06-17
Accepted
2025-06-17 08:24:55
Documents
14
Period of Report
2025-06-17
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0245971-8k_cero.htm   iXBRL 8-K 37538
2 PRESS RELEASE, DATED JUNE 17, 2025 ea024597102ex99-1_cero.htm EX-99.1 11611
  Complete submission text file 0001213900-25-054961.txt   265932

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE cero-20250617.xsd EX-101.SCH 3817
4 XBRL DEFINITION FILE cero-20250617_def.xml EX-101.DEF 26702
5 XBRL LABEL FILE cero-20250617_lab.xml EX-101.LAB 36880
6 XBRL PRESENTATION FILE cero-20250617_pre.xml EX-101.PRE 25326
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0245971-8k_cero_htm.xml XML 6006
Mailing Address 201 HASKINS WAY SUITE 230 SOUTH SAN FRANCISCO CA 94080
Business Address 201 HASKINS WAY SUITE 230 SOUTH SAN FRANCISCO CA 94080 650-407-2376
CERO THERAPEUTICS HOLDINGS, INC. (Filer) CIK: 0001870404 (see all company filings)

EIN.: 871088814 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40877 | Film No.: 251051923
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)